Cardiovascular Outcomes of Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Tirzepatide significantly decreased the risk for a composite endpoint of worsening heart failure or cardiovascular death.

Industry-funded trials of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, reported improved heart failure outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity (STEP-HFpEF; NEJM JW Cardiol Aug 25 2023 and N Engl J Med 2023; 389:1069; STEP-HFpEF DM; NEJM JW Cardiol Apr 6 2024 and N Engl J Med 2024; 390:1394). However, those findings were from exploratory analyses with a relatively short median follow-up time of 52 weeks. In the industry-funded SUMMIT trial (NCT04847557), investigators examined cardiovascular outcomes of tirzepatide — an agonist of glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors — over a longer period in patients with HFpEF and obesity.

The 731 stud…

Reviewing Author

Vlad G. Zaha, MD, PhD, FACC, FAHA

Disclosures

Grant/Research SupportCancer Prevention and Research Institute of Texas; National Institute of Health

Editorial BoardsCirculation

Leadership Positions in Professional SocietiesTexas Chapter of the American College of Cardiology (Section Chair, Cardio-Oncology)

Vlad G. Zaha, MD, PhD, FACC, FAHA

Disclosures

Grant/Research SupportCancer Prevention and Research Institute of Texas; National Institute of Health

Editorial BoardsCirculation

Leadership Positions in Professional SocietiesTexas Chapter of the American College of Cardiology (Section Chair, Cardio-Oncology)

Cardiovascular Outcomes of Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Topics

Reviewing Author